RxDoctor Payments DataLook up a doctor →

Lawrence Newman, MD

Urology · Las Vegas, NVNPI 1568528677

Payments from drug & device makers

$21,785in general payments, 2019–2025

Across 516 payments — averaging $42.22 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Dendreon Pharmaceuticals LLC$9K
  • Sumitomo Pharma America, Inc.$1K
  • Cipla USA Inc.$1K
  • Boston Scientific$959
  • Astellas Pharma US Inc$954
  • Johnson & Johnson$783
  • plus $8K from 50 others

What the payments were for

  • Consulting fees$5,60026%
  • Speaking & faculty fees$1251%
  • Travel & lodging$8794%
  • Food & beverage$14,76468%
  • Education$4172%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$21,785 in reported general payments places this provider in the 80th percentile of 63 urology providers in Nevada.

See all urology providers in Nevada

Medicare billing

Part B allowed, 2024
$503,509
Medicare patients
675
Services billed
6,982

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
OrgovyxRelugolix24$64,643
MyrbetriqMirabegron52$50,371
GemtesaVibegron38$33,866
Tamsulosin Hcl435$5,958
Alfuzosin Hcl ErAlfuzosin Hcl232$4,230
Testosterone15$2,176
Oxybutynin Chloride ErOxybutynin Chloride48$1,703
Silodosin14$1,273
Potassium Citrate ErPotassium Citrate12$1,237
Testosterone Cypionate25$1,100
Solifenacin Succinate19$1,064
Amoxicillin-Clavulanate PotassAmoxicillin/Potassium Clav134$858
Bethanechol Chloride20$807
Finasteride70$666
Estradiol14$643

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Sumitomo Pharma America, Inc.Orgovyx, Gemtesa$1,260$98,50962 claims
Astellas Pharma US IncMyrbetriq$954$50,37152 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 80th percentile of 63 urology providers in Nevada.

Other urology in Las Vegas

See the full list for Nevada

Where these figures come from

Is this you, or does something look wrong? →